330
Participants
Start Date
May 31, 2002
Primary Completion Date
July 31, 2012
Study Completion Date
July 31, 2012
Trastuzumab
8mg/kg IV on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycle 2 up a maximum of Cycle 17
Doxorubicin
60 mg/m2 IV on Day 1 of Cycles 1 through 3
Paclitaxel
150 mg/m2 IV on Day 1 of Cycles 1 through 3, followed by 175 mg/m2 IV on Day 1 of Cycles 4 through 7
CMF
CMF: Cyclophosphamide (600 mg/m2 IV bolus), methotrexate (40 mg/m2 IV bolus), 5-fluorouracil (600 mg/m2 IV bolus) on Day 1 of Cycles 8 through 10
Vienna
Jerez de la Frontera
Donostia / San Sebastian
Milan
Varese
Pavia
Madrid
Mirano
Castelfranco Veneto
Bellunoi
Udine
Santorso
Vicenza
Trento
Bologna
Carpi
Valencia
Valencia
Zaragoza
Pisa
San Giovanni Rotondo
München
Moscow
Moscow
Moscow
Moscow
Saint Petersburg
Saint Petersburg
Kazan'
Sassari
Lisbon
Barcelona
Barcelona
Barcelona
Barcelona
Terrassa
Hoffmann-La Roche
INDUSTRY